NPS Pharma Drug for Bowel Condition Meets Study Goals
This article is for subscribers only.
NPS Pharmaceuticals Inc. said its experimental therapy, Gattex, helped restore normal intestinal function in patients with a rare bowel condition in a study, spurring shares to the biggest gain in about 11 years.
NPS increased $2.39, or 31 percent, to $10 at 4 p.m. New York time in Nasdaq Stock Market composite trading. It was the stock’s largest one-day percentage jump since Feb. 17, 2000. The shares have almost tripled in the past 12 months.